How much funding has CuraSen Therapeutics raised?

CuraSen Therapeutics has raised $60.3M in total funding, most recently a Grant round.

What industry is CuraSen Therapeutics in?

CuraSen Therapeutics operates in Biotech, Healthcare.

CuraSen Therapeutics

Q: Who are CuraSen Therapeutics's investors?

CuraSen Therapeutics's investors include Alzheimer's Drug Discovery Foundation, New Leaf Venture Partners, Alta Partners.

Rethinking Brain Disease

Biotech

Healthcare

Business Model: B2B
Website: curasen.com
Total Funding: $60.3M

Last Round: $5.8M GrantOct 2023
Rounds: 2

About

CuraSen Therapeutics is a privately funded biopharmaceutical company pursuing development of novel treatments for psychiatric and neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, PSP, and ALS. The company is rethinking prevailing therapeutic approaches by targeting the loss of noradrenergic signaling in the degenerating brain — specifically developing treatments that activate adrenergic receptors to restore cognitive function and brain health. CuraSen's lead program, CuraAX (CST-3056), is in Phase 1 clinical trials for neurogenic orthostatic hypotension in Parkinson's disease patients. The company is backed by investors including New Leaf Venture Partners, Longitude Capital, J&J Innovation, and the Alzheimer's Drug Discovery Foundation.

Summary

CuraSen Therapeutics is a Biotech company. It has raised $60.3M in total across 2 rounds, most recently a $5.8M Grant round in Oct 2023. Investors include Alzheimer's Drug Discovery Foundation, New Leaf Venture Partners and Alta Partners.